Syndax Pharmaceuticals (SNDX) Accumulated Expenses (2015 - 2026)

Syndax Pharmaceuticals' Accumulated Expenses history runs 12 years deep, the most recent figure standing at $74.8 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 911.12% year-over-year to $74.8 million; the TTM figure through Mar 2026 stood at $74.8 million (up 911.12% YoY), while the FY2025 annual figure was $103.1 million, up 71.5% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $74.8 million, down from $103.1 million in the prior quarter.
• The five-year high for Accumulated Expenses was $103.1 million in Q4 2025, with the low at $1.9 million in Q1 2022.
• The 5-year median for Accumulated Expenses is $24.3 million (2022), against an average of $31.3 million.
• The sharpest annual moves came in 2024 and 2025: Accumulated Expenses surged 994.2% in 2024, then sank 77.84% in 2025.
• Syndax Pharmaceuticals' Accumulated Expenses stood at $24.3 million in 2022, then soared by 64.18% to $39.9 million in 2023, then soared by 50.78% to $60.1 million in 2024, then surged by 71.5% to $103.1 million in 2025, then dropped by 27.38% to $74.8 million in 2026.
• Business Quant data shows SNDX's Accumulated Expenses at $74.8 million in Q1 2026, $103.1 million in Q4 2025, and $15.6 million in Q3 2025.